Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Higgins, D. Altman, P. Gøtzsche, P. Jüni, D. Moher, A. Oxman, J. Savović, K. Schulz, L. Weeks, J. Sterne (2011)
The Cochrane Collaboration’s tool for assessing risk of bias in randomised trialsThe BMJ, 343
M. Valgimigli, H. Bueno, R. Byrne, J. Collet, F. Costa, A. Jeppsson, P. Jüni, A. Kastrati, P. Kolh, L. Mauri, G. Montalescot, F. Neumann, Mate Peticevic, M. Roffi, P. Steg, S. Windecker, J. Zamorano (2018)
ArrayKardiologia polska, 75 12
D. Moher, A. Liberati, J. Tetzlaff, D. Altman (2009)
METHODS OF SYSTEMATIC REVIEWS AND META-ANALYSIS Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
D. Alexopoulos, I. Xanthopoulou, S. Deftereos, M. Hamilos, G. Sitafidis, I. Kanakakis, Ioanna Pentara, M. Vavouranakis, P. Davlouros, G. Hahalis, J. Goudevenos (2016)
Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1‐year outcomes from the GReek AntiPlatElet (GRAPE) RegistryJournal of Thrombosis and Haemostasis, 14
A. Stang (2010)
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEuropean Journal of Epidemiology, 25
H. Watti, Khagendra Dahal, H. Zabher, Pavan Katikaneni, K. Modi, A. Abdulbaki (2017)
Comparison of prasugrel and ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: A meta-analysis of randomized and non-randomized studies.International journal of cardiology, 249
G. Parodi, Benedetta Bellandi, R. Valenti, A. Migliorini, R. Marcucci, N. Carrabba, L. Giurlani, G. Gensini, R. Abbate, D. Antoniucci (2014)
Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study.American heart journal, 167 6
G. Parodi, R. Valenti, Benedetta Bellandi, A. Migliorini, R. Marcucci, V. Comito, N. Carrabba, A. Santini, G. Gensini, R. Abbate, D. Antoniucci (2013)
Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study.Journal of the American College of Cardiology, 61 15
D. Moher, A. Liberati, J. Tetzlaff, D. Altman (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA StatementPLoS Medicine, 6
C. Song, Devraj Sukul, Milan Seth, J. Dupree, A. Khandelwal, S. Dixon, D. Wohns, Thomas Lalonde, H. Gurm (2017)
Ninety-Day Readmission and Long-Term Mortality in Medicare Patients (≥65 Years) Treated With Ticagrelor Versus Prasugrel After Percutaneous Coronary Intervention (from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium).The American journal of cardiology, 120 11
F. Costa, D. Klaveren, S. James, D. Heg, L. Räber, F. Feres, T. Pilgrim, M. Hong, Hyo‐Soo Kim, A. Colombo, P. Steg, T. Zanchin, T. Palmerini, L. Wallentin, Deepak Bhatt, G. Stone, S. Windecker, E. Steyerberg, M. Valgimigli (2017)
Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trialsThe Lancet, 389
J. Higgins, S. Green, J. Higgins (2013)
Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0. The Cochrane Collaboration
L. Bonello, M. Laine, M. Cluzel, C. Frère, J. Mancini, Aurasse Hasan, F. Thuny, M. Gaubert, R. Guieu, F. Dignat-George, P. Michelet, F. Paganelli, F. Kerbaul (2015)
Comparison of Ticagrelor Versus Prasugrel to Prevent Periprocedural Myonecrosis in Acute Coronary Syndromes.The American journal of cardiology, 116 3
L. Mauri, D. Kereiakes, Robert Yeh, Priscilla Driscoll-Shempp, D. Cutlip, P. Steg, Sharon-Lise Normand, Eugene, Braunwald, S. Wiviott, David Cohen, David Holmes, Mitchell Krucoff, J. Hermiller, H. Dauerman, I. Daniel, Simon, D. Kandzari, Kirk Garratt, David Lee, Thomas Pow, Peter Lee, Michael Rinaldi, Joseph Massaro (2014)
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.The New England journal of medicine, 371 23
Glenn Levine, Eric Bates, Laura Mauri, J. Bittl, Roxana Mehran, R. Brindis, D. Mukherjee, Stephan Fihn, L. Newby, Lee Fleisher, P. O'Gara, Christopher Granger, M. Sabatine, Richard Lange, Peter Smith, Michael Mack, Sidney Smith, Lesley Curtis, S. Pressler, D. Wijeysundera (2016)
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.Journal of the American College of Cardiology, 68 10
R. Dersimonian, R. Kacker (2007)
Random-effects model for meta-analysis of clinical trials: an update.Contemporary clinical trials, 28 2
Goutham Rao, F. Lopez‐Jimenez, J. Boyd, F. D'Amico, N. Durant, M. Hlatky, G. Howard, Katherine Kirley, Christopher Masi, T. Powell-Wiley, A. Solomonides, C. West, J. Wessel (2017)
Methodological Standards for Meta-Analyses and Qualitative Systematic Reviews of Cardiac Prevention and Treatment Studies: A Scientific Statement From the American Heart Association.Circulation, 136 10
H Bueno M Valgimigli (2018)
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTSThe Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)Eur Heart J., 39
Choongki Kim, D. Shin, C. Ahn, Jung‐Sun Kim, Byeong‐Keuk Kim, Y. Ko, D. Choi, M. Hong, Ju-Heon Park, H. Lee, Y. Choi, Youn Choi, Sang-Kwon Oh, Y. Jang (2017)
The Use Pattern and Clinical Impact of New Antiplatelet Agents Including Prasugrel and Ticagrelor on 30-day Outcomes after Acute Myocardial Infarction in Korea: Korean Health Insurance Review and Assessment DataKorean Circulation Journal, 47
J. Dery, S. Mehta, H. Fisher, Xiang Zhang, Y. Zhu, R. Welsh, S. Lavi, T. Cieza, M. Henderson, S. Lutchmedial, A. Siega, A. Cheema, B. Wong, A. Kokis, P. Dehghani, S. Goodman (2016)
Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (COAPT).American heart journal, 181
L. Wallentin, R. Becker, A. Budaj, C. Cannon, H. Emanuelsson, C. Held, J. Horrow, S. Husted, S. James, H. Katus, K. Mahaffey, B. Scirica, A. Skene, P. Steg, R. Storey, R. Harrington, A. Freij, M. Thorsén (2009)
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.The New England journal of medicine, 361 11
M. Laine, C. Frère, R. Toesca, J. Berbis, P. Barnay, M. Pansieri, P. Michelet, J. Bessereau, Élise Camilleri, O. Ronsin, O. Helal, F. Paganelli, F. Dignat-George, L. Bonello (2013)
Ticagrelor versus prasugrel in diabetic patients with an acute coronary syndromeThrombosis and Haemostasis, 111
M. Rasia, E. Solinas, M. Marino, P. Guastaroba, A. Menozzi, M. Cattabiani, I. Tadonio, R. Palma, L. Vignali (2017)
Comparison of 4 different strategies of DAPT after PCI in ACS real world population from a Northern Italy registryJournal of Thrombosis and Thrombolysis, 44
S. Wiviott, E. Braunwald, C. Mccabe, G. Montalescot, W. Rużyłło, S. Gottlieb, F. Neumann, D. Ardissino, Stefano Servi, S. Murphy, J. Riesmeyer, G. Weerakkody, M. Gibson, E. Antman (2007)
Prasugrel versus clopidogrel in patients with acute coronary syndromes.The New England journal of medicine, 357 20
Z. Motovska, O. Hlinomaz, P. Kala, M. Hromadka, J. Knot, I. Varvarovsky, J. Dusek, Jirí Jarkovský, R. Miklik, R. Rokyta, F. Toušek, Petra Kramáriková, M. Svoboda, B. Majtan, S. Simek, M. Branny, J. Mrózek, P. Červinka, J. Ostřanský, P. Widimsky (2018)
1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor.Journal of the American College of Cardiology, 71 4
D. Alexopoulos, I. Xanthopoulou, V. Gkizas, G. Kassimis, K. Theodoropoulos, G. Makris, N. Koutsogiannis, A. Damelou, Grigorios Tsigkas, P. Davlouros, G. Hahalis (2012)
Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients with ST-Segment–Elevation Myocardial InfarctionCirculation: Cardiovascular Interventions, 5
S. Husted, S. James, R. Becker, J. Horrow, H. Katus, R. Storey, C. Cannon, M. Heras, R. Lopes, J. Morais, K. Mahaffey, R. Bach, D. Wojdyla, L. Wallentin (2012)
Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes: A Substudy From the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) TrialCirculation: Cardiovascular Quality and Outcomes, 5
C. Larmore, M. Effron, C. Molife, M. DeKoven, Y. Zhu, Jingsong Lu, S. Karkare, H. Lieu, Won Lee, G. Vetrovec (2015)
“Real‐World” Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United StatesCatheterization and Cardiovascular Interventions, 88
Green S Higgins JPT (2011)
//www.handbook.cochrane.org. Accessed 4 Oct 2018.
O. Backer, H. Ratcovich, L. Biasco, F. Pedersen, S. Helqvist, K. Saunamaki, H. Tilsted, P. Clemmensen, G. Olivecrona, H. Kelbaek, E. Jørgensen, T. Engstrøm, L. Holmvang (2015)
Prehospital administration of P2Y12 inhibitors and early coronary reperfusion in primary PCI: an observational comparative studyThrombosis and Haemostasis, 114
M. Yudi, D. Clark, O. Farouque, D. Eccleston, N. Andrianopoulos, S. Duffy, S. Duffy, A. Brennan, J. Lefkovits, J. Ramchand, T. Yip, E. Oqueli, Christopher Reid, Christopher Reid, A. Ajani, A. Ajani, A. Ajani (2016)
Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary interventionInternal Medicine Journal, 46
J. Higgins, S. Thompson, J. Deeks, D. Altman (2003)
Measuring inconsistency in meta-analysesBMJ : British Medical Journal, 327
S. Schulz, D. Angiolillo, D. Antoniucci, I. Bernlochner, C. Hamm, J. Jaitner, K. Laugwitz, K. Mayer, B. Merzljak, T. Morath, F. Neumann, G. Richardt, J. Ruf, Gisela Schömig, H. Schühlen, H. Schunkert, A. Kastrati, Intracoronary Investigators (2014)
Randomized Comparison of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome and Planned Invasive Strategy—Design and Rationale of the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 5 TrialJournal of Cardiovascular Translational Research, 7
G. Biondi-Zoccai, M. Lotrionte, P. Agostoni, A. Abbate, E. Romagnoli, G. Sangiorgi, D. Angiolillo, M. Valgimigli, L. Testa, F. Gaita, I. Sheiban (2011)
Adjusted indirect comparison meta-analysis of prasugrel versus ticagrelor for patients with acute coronary syndromes.International journal of cardiology, 150 3
Abstract Background The newer P2Y12 inhibitors have better efficacy than clopidogrel. However, whether ticagrelor or prasugrel have a better comparative safety and efficacy profile, especially in the long-term, remains inconclusive. Objective We compared prasugrel and ticagrelor in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). Methods MEDLINE and the Cochrane library were queried for randomized controlled trials (RCTs) or observational studies comparing prasugrel with ticagrelor in patients with ACS undergoing PCI. Random-effects pooling was used to calculate odds ratios (ORs) with 95% confidence intervals (CI). Analyses were stratified by duration of follow-up (short term [≤ 3 months] and long term [≥ 1 year]) and study design. Results In total, 14 studies (six RCTs, eight observational studies), including 40,188 patients, met eligibility criteria. Pooled analysis did not indicate that prasugrel significantly decreased all-cause mortality compared with ticagrelor in the short term (OR 0.49; 95% CI 0.20–1.20; p = 0.11) or long term (OR 0.74; 95% CI 0.48–1.15; p = 0.38). Pooled observational studies showed significantly lower long-term all-cause mortality (OR 0.63; 95% CI 0.43–0.92; p = 0.02) and short-term stent thrombosis (OR 0.46; 95% CI 0.28–0.75; p = 0.002) with prasugrel. No significant difference was observed in the risk of nonfatal myocardial infarction, ischemic stroke, bleeding, or repeat revascularization between the two groups. Results remained similar after stratification according to follow-up and study design. Conclusions The present analysis suggests that prasugrel might have a better efficacy profile than ticagrelor in patients with ACS undergoing PCI. However, this advantage was only seen in pooled observational studies and is likely to be affected by selection bias.
American Journal of Cardiovascular Drugs – Springer Journals
Published: Oct 1, 2019
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.